Summary
This 8-K/A filing from Bristol-Myers Squibb Company (BMY) amends a previous 8-K filing dated July 26, 2007, which announced the company's second-quarter 2007 financial results. The amendment primarily provides revised supplemental financial information that was originally posted on the company's website. This supplemental data includes more detailed net sales, months on hand, and estimated demand for key products across its International Pharmaceutical, Nutritionals, and Other Health Care segments. Investors should note that this filing is an amendment to clarify and provide updated details on specific financial metrics as of June 30, 2007, with comparative data also available for March 31, 2007, and for the previous year (March 31, 2006, and June 30, 2006). While the core financial results were announced previously, this filing enhances transparency regarding product-level performance and inventory management within the company's key reporting segments.
Key Highlights
- 1Amendment to a previous 8-K filing reporting Q2 2007 financial results.
- 2Revised supplemental financial information is provided as Exhibit 99.2.
- 3Supplemental data includes net sales for key products in International Pharmaceutical, Nutritionals, and Other Health Care segments.
- 4Information on 'months on hand' for key products is updated.
- 5Estimated demand information for key products is also revised.
- 6Data is presented as of June 30, 2007, with comparative figures for March 31, 2007, and previous year periods (June 30, 2006, March 31, 2006).
- 7This filing serves to provide greater detail and clarity on the company's operational and financial performance metrics.